3 Magnificent Growth Stocks to Buy Right Now

Group 1: AstraZeneca - AstraZeneca is considered an underrated growth stock with significant potential, despite a recent decline of over 11% in the past six months [2] - The company reported a revenue increase of 21% in 2024, reaching $54 billion, and projects continued growth in the high single digits for the current year, with expectations to reach$80 billion in sales by 2030 [3][4] - AstraZeneca is focusing on expanding its oncology, biopharmaceutical, and rare-disease portfolios, supported by recent acquisitions, including Amolyt Pharma and Fusion Pharmaceuticals [4] - The stock is trading at a price-to-earnings-growth multiple of around 0.9, indicating excellent long-term value, along with a dividend yield of 2% [5] Group 2: Eli Lilly - Eli Lilly is a leader in the rapidly growing weight loss market, driven by the success of tirzepatide, which is also used for diabetes treatment [6] - The company has a diversified portfolio with strong products in oncology and immunology, including Verzenio and Taltz, and is expected to continue revenue growth [7][9] - Eli Lilly has several new products in its pipeline that could generate over $1 billion in annual sales, including treatments for Alzheimer's, eczema, and ulcerative colitis [8] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals has delivered over 320% returns over the past decade, with expectations for future growth driven by recent FDA approvals for Alyftrek and Journavx [10][11] - The company is launching Casgevy, a treatment for sickle cell disease, with over 50 authorized treatment centers worldwide, anticipating significant patient growth [12] - Vertex's pipeline includes promising programs targeting kidney diseases and severe type 1 diabetes, enhancing its attractiveness as a growth stock [13]